What's in JESSICA GARCIA SUAREZ's pipeline?

JESSICA GARCIA SUAREZ has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with JESSICA GARCIA SUAREZ's portfolio?

Top competitors by shared drug class: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Washington University School of Medicine.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jessica-garcia-suarez.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

JESSICA GARCIA SUAREZ — Portfolio Competitive Intelligence Brief

JESSICA GARCIA SUAREZ pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
COLD BLOOD BASED CARDIOPLEGIA	COLD BLOOD BASED CARDIOPLEGIA	marketed	Cardioplegic solution		Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 shared drug class
Washington University School of Medicine · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for JESSICA GARCIA SUAREZ:

Cite this brief

Drug Landscape (2026). JESSICA GARCIA SUAREZ — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jessica-garcia-suarez. Accessed 2026-05-16.